Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 30;13:6303–6314. doi: 10.2147/OTT.S250412

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Nie et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The expression levels of GRHL2 were up-regulated in the cisplatin-resistant SOC tissues and cells, which affected the prognosis of SOC patients. (A) The expression levels of GRHL2 protein in normal ovary and SOC tissues (n=80) were detected by immunohistochemistry. (magnification, ×100,×400) (B) The expression score of GRHL2 in resistant SOC tissues (n=29) was drastically higher than those in sensitive SOC tissues (n=51). *P < 0.05 vs sensitive. (C, D) Progression-free survival curves and overall survival curves of SOC patients were analyzed by Kaplan-Meier according to GRHL2 expression (n=80). (E–G) The relative mRNA and protein levels of GRHL2 were detected in SKOV3/DDP and SKOV3 cells. *P < 0.05 vs SKOV3.

Note: Data were expressed as mean±SD.

Abbreviation: SOC, serous ovarian cancer.